These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36831513)

  • 1. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines.
    Xu S; Miura K; Shukuya T; Harada S; Fujioka M; Winardi W; Shimamura S; Kurokawa K; Sumiyoshi I; Miyawaki T; Asao T; Mitsuishi Y; Tajima K; Takahashi F; Hayashi T; Harada N; Takahashi K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.
    Wang Y; Chen H; Zhang T; Yang X; Zhong J; Wang Y; Chi Y; Wu M; An T; Li J; Zhao X; Dong Z; Wang Z; Zhao J; Zhuo M; Huang J
    Ann Transl Med; 2021 Jan; 9(1):33. PubMed ID: 33553326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
    Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
    Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial translocation contributes to cachexia from locally advanced gastric cancer.
    Mi L; Lin J; Zheng H; Xu X; Zhang J; Zhang D
    Hepatogastroenterology; 2012 Oct; 59(119):2348-51. PubMed ID: 22709824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients.
    Punzi T; Fabris A; Morucci G; Biagioni P; Gulisano M; Ruggiero M; Pacini S
    Mol Diagn Ther; 2012 Apr; 16(2):115-24. PubMed ID: 22497530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
    Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
    Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.
    Miyawaki T; Naito T; Kodama A; Nishioka N; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Murakami H; Notsu A; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    JTO Clin Res Rep; 2020 Jun; 1(2):100020. PubMed ID: 34589927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
    Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
    Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia.
    Lima JDCC; Simoes E; de Castro G; Morais MRPT; de Matos-Neto EM; Alves MJ; Pinto NI; Figueredo RG; Zorn TMT; Felipe-Silva AS; Tokeshi F; Otoch JP; Alcantara P; Cabral FJ; Ferro ES; Laviano A; Seelaender M
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1045-1059. PubMed ID: 31273954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
    de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
    Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
    Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
    Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia.
    Eskiler GG; Bezdegumeli E; Ozman Z; Ozkan AD; Bilir C; Kucukakca BN; Ince MN; Men AY; Aktas O; Horoz YE; Akpinar D; Genc I; Kaleli S
    Bratisl Lek Listy; 2019; 66(11):819-826. PubMed ID: 31747761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of cytokine levels in cachectic patients with prostate carcinoma.
    Pfitzenmaier J; Vessella R; Higano CS; Noteboom JL; Wallace D; Corey E
    Cancer; 2003 Mar; 97(5):1211-6. PubMed ID: 12599227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.
    Talbert EE; Lewis HL; Farren MR; Ramsey ML; Chakedis JM; Rajasekera P; Haverick E; Sarna A; Bloomston M; Pawlik TM; Zimmers TA; Lesinski GB; Hart PA; Dillhoff ME; Schmidt CR; Guttridge DC
    J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):358-368. PubMed ID: 29316343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
    Rounis K; Makrakis D; Tsigkas AP; Georgiou A; Galanakis N; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Vardakis N; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
    Transl Lung Cancer Res; 2021 Aug; 10(8):3538-3549. PubMed ID: 34584855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
    Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
    Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.